ES2791879T3 - Tratamiento de diabetes mediante el uso de GLP-1 y anti-IL-21 - Google Patents

Tratamiento de diabetes mediante el uso de GLP-1 y anti-IL-21 Download PDF

Info

Publication number
ES2791879T3
ES2791879T3 ES15720982T ES15720982T ES2791879T3 ES 2791879 T3 ES2791879 T3 ES 2791879T3 ES 15720982 T ES15720982 T ES 15720982T ES 15720982 T ES15720982 T ES 15720982T ES 2791879 T3 ES2791879 T3 ES 2791879T3
Authority
ES
Spain
Prior art keywords
glp
agonist
inhibitor
peptide
function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15720982T
Other languages
English (en)
Spanish (es)
Inventor
Ken Coppieters
Herrath Matthias Von
Tamar Boursalian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority claimed from PCT/EP2015/059811 external-priority patent/WO2015169789A1/en
Application granted granted Critical
Publication of ES2791879T3 publication Critical patent/ES2791879T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES15720982T 2014-05-07 2015-05-05 Tratamiento de diabetes mediante el uso de GLP-1 y anti-IL-21 Active ES2791879T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461989841P 2014-05-07 2014-05-07
EP14169596 2014-05-23
EP14189732 2014-10-21
PCT/EP2015/059811 WO2015169789A1 (en) 2014-05-07 2015-05-05 Treatment of diabetes type 1 using glp-1 and anti-il-21

Publications (1)

Publication Number Publication Date
ES2791879T3 true ES2791879T3 (es) 2020-11-06

Family

ID=70609983

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15720982T Active ES2791879T3 (es) 2014-05-07 2015-05-05 Tratamiento de diabetes mediante el uso de GLP-1 y anti-IL-21

Country Status (6)

Country Link
JP (1) JP6824373B2 (da)
DK (1) DK3139948T3 (da)
ES (1) ES2791879T3 (da)
HR (1) HRP20200763T1 (da)
HU (1) HUE048860T2 (da)
PT (1) PT3139948T (da)

Also Published As

Publication number Publication date
JP6824373B2 (ja) 2021-02-03
HRP20200763T1 (hr) 2020-07-24
JP2020073501A (ja) 2020-05-14
PT3139948T (pt) 2020-05-22
HUE048860T2 (hu) 2020-09-28
DK3139948T3 (da) 2020-05-25

Similar Documents

Publication Publication Date Title
US10335462B2 (en) Use of long-acting GLP-1 peptides
ES2799099T3 (es) Proteínas de fusión
ES2833458T3 (es) Compuestos coagonistas de glucagón y de GLP-1
ES2390270T3 (es) Compuestos de GLP-1 unidos a polietilenglicol
TWI643637B (zh) 長效胰促泌素肽接合物之液體製劑
US20110020345A1 (en) Drug fusions and conjugates
JP5524620B2 (ja) 持続性血糖降下剤の投与方法
JP2020533302A (ja) 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１
US10105442B2 (en) Treatment of diabetes type 1 using GLP-1 and anti-IL-21
ES2791879T3 (es) Tratamiento de diabetes mediante el uso de GLP-1 y anti-IL-21
ES2767705T3 (es) Nuevos análogos de glucagón
ES2796839T3 (es) Uso de péptidos GLP-1 de acción prolongada